Mary Chapman, features writer —

Mary graduated from Wayne State University with a degree in journalism. She began her career at United Press International, then spent a decade reporting for the Bureau of National Affairs, Inc. (now Bloomberg Industry Group). Mary has written extensively for The New York Times, and her work has appeared in publications such as Time, Newsweek, Fortune, and the Chicago Tribune. She’s won a Society of Professional Journalists award for outstanding reporting.

Articles by Mary Chapman

Partnership Leads to New and Unique Registry for HAE Patients

A new hereditary angioedema (HAE) registry, touted as the first of its kind, is using real-world data to provide comprehensive insights into patients’ journeys. The Trio-CIIC HAE Registry derives from a partnership between real-world data provider Trio Health and the Consortium of Independent Immunology Clinics (CIIC), a professional organization…

Advocates to Mark HAE Awareness Day on May 16 by ‘Stepping Up’

HAE Awareness Day is observed around the world each May 16 to bring attention to hereditary angioedema (HAE) and those people the disorder affects. The goal is to heighten awareness among the general public, as well as healthcare professionals, decision-makers, and industry representatives. The theme for this year’s observance…

Takeda Canada Seeks AI, Digital Solutions With Innovation Challenge

With a goal of finding new digital technologies and artificial intelligence (AI) solutions for patients with rare genetic disorders like hereditary angioedema (HAE), and for inflammatory bowel diseases, Takeda Canada has introduced an innovation challenge. Specifically, Takeda Canada is seeking new and breakthrough solutions in early diagnosis, as…

Cycle Launches Sajazir as Treatment Option for Acute HAE Attacks

Cycle Pharmaceuticals has launched Sajazir, an injectable form of icatibant, as a new treatment option for acute attacks of hereditary angioedema (HAE) in adults. Patients who use Sajazir can take advantage of Cycle Vita, the company’s recently created rare disease product support hub. Icatibant, also sold as Firazyr,…

EveryLife Introduces First of Kind ‘Roadmap’ to ICD Codes

To help patient advocacy leaders and their partners better understand how global health statistics codes — known as ICD codes — are assigned, updated, and revised in the U.S. health information system, the EveryLife Foundation for Rare Diseases is presenting a first-of-its-kind resource guide. The foundation created the…

Rare Disease Day at NIH, Set for March 1, Growing Year by Year

Rare Disease Day at NIH, organized by the National Institutes of Health (NIH) and taking place on March 1, will feature panel discussions, patient stories, research updates, TED-style talks, and a presentation by a Nobel laureate recently recognized for her work on a gene editing tool. The free, virtual…

Pandemic Won’t Stop Rare Disease Day on Feb. 28

Scores of virtual events are afoot around the world to mark Rare Disease Day 2021 on Feb. 28. The activities are focused on heightening awareness about rare diseases and the hundreds of millions of individuals they are thought to affect. Patients, caregivers, and advocates worldwide will sport denim ribbons…